ObesityNCT02902198
Taste Physiology in Obese Volunteers Before and After Bariatric Surgery
A study testing Glucose, Monosodium glutamate and Quinine in people with Obesity, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
The objective is to investigate neuro-anatomical correlates of gastrointestinal taste stimulation by means of functional MRI before and after bariatric surgery. Intragastric administration of glucose, monosodium glutamate, chloroquine and placebo is followed by functional brain MRI in obese humans before and 3 months… Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Obesity
- What is being tested?
- Glucose, Monosodium glutamate and Quinine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- 1 siteSwitzerland
- Study dates
- Dec 2014to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- morbidly obese patients (BMI min 35kg/m2) scheduled for bariatric surgery
- right handed
Who cannot join
- cardiovascular disease
- neurologic/psychiatric disorders
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Bettina Wölnerhanssen, Dr contact
Switzerland1 site, 1 recruiting
- Recruiting
University Hopital Basel
Basel
Bettina Wölnerhanssen, Dr, bettina.woelnerhanssen@usb.ch
About this study
The objective is to investigate neuro-anatomical correlates of gastrointestinal taste stimulation by means of functional MRI before and after bariatric surgery. Intragastric administration of glucose, monosodium glutamate, chloroquine and placebo is followed by functional brain MRI in obese humans before and 3 months after surgery.
- Conditions
- Obesity
- Being tested
- Placebo, Glucose, Monosodium glutamate, Quinine
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDietary supplement
Tap water 200ml
GlucoseDietary supplement
25g Glucose in 200ml tap water
Monosodium glutamateDietary supplement
1g monosodium glutamate in 200ml tap water
QuinineDietary supplement
17mg quinine in 200ml tap water
| Study group | Role | What they receive |
|---|---|---|
| Placebo preoperative | Placebo comparator | Single intragastric instillation of 200ml tap water via nasogastric tube Receives: Dietary Supplement: Placebo |
| Placebo postoperative | Placebo comparator | Single intragastric instillation of 200ml tap water via nasogastric tube Receives: Dietary Supplement: Placebo |
| Glucose preoperative | Active comparator | Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube Receives: Dietary Supplement: Glucose |
| Glucose postoperative | Active comparator | Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube Receives: Dietary Supplement: Glucose |
| Monosodium glutamate preoperative | Active comparator | Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube Receives: Dietary Supplement: Monosodium glutamate |
| Monosodium glutamate postoperative | Active comparator | Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube Receives: Dietary Supplement: Monosodium glutamate |
| Quinine preoperative | Active comparator | Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube Receives: Dietary Supplement: Quinine |
| Quinine postoperative | Active comparator | Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube Receives: Dietary Supplement: Quinine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effect of tastants on cerebral blood flow measured by functional brain MRI
Measured: changes from baseline to one hour after treatment
Secondary outcomes (2)
Effect of tastants plasma glucagon-like peptide (GLP-1) concentrations
Measured: changes from baseline to one hour after treatment
Effect of tastants plasma ghrelin concentrations
Measured: changes from baseline to one hour after treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2016 (estimated)
- Study startDec 2014
- Primary completionDec 2026 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Christoph Beglinger, Prof, Study chair, University Basel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02902198
- Sponsor's protocol ID
- fMRI Taste 2
- Status last verified
- Mar 2025
- First submitted
- 12 Sep 2016
- Last updated
- 3 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Taste Physiology in Obese Volunteers Before and After Bariatric Surgery
- ClinicalTrials.gov ID
- NCT02902198
- Acronym / sponsor ID
- fMRI Taste 2
- Conditions
- Obesity
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 16 participants (estimated)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- Dec 2014 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 15 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective is to investigate neuro-anatomical correlates of gastrointestinal taste stimulation by means of functional MRI before and after bariatric surgery. Intragastric administration of glucose, monosodium glutamate, chloroquine and placebo is followed by functional brain MRI in obese humans before and 3 months after surgery.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Placebo preoperative | Placebo comparator | Dietary Supplement: PlaceboSingle intragastric instillation of 200ml tap water via nasogastric tube |
| Placebo postoperative | Placebo comparator | Dietary Supplement: PlaceboSingle intragastric instillation of 200ml tap water via nasogastric tube |
| Glucose preoperative | Active comparator | Dietary Supplement: GlucoseSingle intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube |
| Glucose postoperative | Active comparator | Dietary Supplement: GlucoseSingle intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube |
| Monosodium glutamate preoperative | Active comparator | Dietary Supplement: Monosodium glutamateSingle intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube |
| Monosodium glutamate postoperative | Active comparator | Dietary Supplement: Monosodium glutamateSingle intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube |
| Quinine preoperative | Active comparator | Dietary Supplement: QuinineSingle intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube |
| Quinine postoperative | Active comparator | Dietary Supplement: QuinineSingle intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- morbidly obese patients (BMI min 35kg/m2) scheduled for bariatric surgery
- right handed
Key exclusion criteria (2 listed)
- cardiovascular disease
- neurologic/psychiatric disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboTap water 200ml | Dietary supplement | Placebo postoperative, Placebo preoperative |
| Glucose25g Glucose in 200ml tap water | Dietary supplement | Glucose postoperative, Glucose preoperative |
| Monosodium glutamate1g monosodium glutamate in 200ml tap water | Dietary supplement | Monosodium glutamate postoperative, Monosodium glutamate preoperative |
| Quinine17mg quinine in 200ml tap water | Dietary supplement | Quinine postoperative, Quinine preoperative |
Primary outcome
Effect of tastants on cerebral blood flow measured by functional brain MRI
Time frame: changes from baseline to one hour after treatment
2 secondary outcomes
Effect of tastants plasma glucagon-like peptide (GLP-1) concentrations
Time frame: changes from baseline to one hour after treatment
Effect of tastants plasma ghrelin concentrations
Time frame: changes from baseline to one hour after treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Bettina Wölnerhanssen, Dr contact
Christoph Beglinger, Prof study chair
University Basel
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Glucose, Monosodium glutamate and Quinine in people with Obesity, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bettina Wölnerhanssen, Dr (bettina.woelnerhanssen@usb.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effect of tastants on cerebral blood flow measured by functional brain MRI (time frame: changes from baseline to one hour after treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2025.